PDL BioPharma Inc

PDL BioPharma — Investor Presentation (October 2019)

30 slides from PDL BioPharma's investor presentation, Oct 21, 2019

  1. Slide 1: LENSAR: Global Leader in Next Generation Femtosecond Cataract Laser Technology

    A | LENSAR Nick Curtis, CEO October 2019 Global Leader in Next Generation Femtosecond Cataract Laser Technology for Refractive Cataract Surgery ‘f your femtosecond cataract laser hasn't evolved, it’s probably extinct @& LENSAR

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements

  3. Slide 3: Visually Significant Astigmatism Exists in Almost All People Who Need Cataract Surgery

    Visually Significant Astigmatism Exists in Almost All People Who Need Cataract Surgery but \Remains Uncorrected Post-Cataract Surgery with Post-Cataract Surgery Pre-Cataract Surgery Visually Significant Astigmatism With Astigmatism Corrected + Glasses donothelpvision + Glassesneededtoseeclearlyatall

  4. Slide 4: LENSAR's Mission: Surgeon and Patient-Centric Always

    LENSAR’s Mission: Surgeon and,Patient-Centric— Always Provide Superior Technology for the Treatment of Cataracts and Management of Astigmatism to Achieve Superior Outcomes for Patients Through Better Precision, Reproducibility and Lens Placement Positioning

  5. Slide 5: Investment Highlights

    Investment Highlights Leading Innovator of Femtosecond Cataract Lasers (FLS) ina Growing Cataract Surgery Market + Innovation Leader: Proprietary laser system leads the market in innovation + Best-in-Class Technology Platform: LENSAR Streamline? IV ~ Currently available Streamline® IV - enables opti

  6. Slide 6: Focus on Innovative Laser Technology for Use in all Cataracts

    Focus on Innovative Laser Technology for Use in all Cataracts Best-in-Class Technology Platform: LENSAR Streamline® IV ~ Currently available Streamline® IV - enables optimal treatment of tissue-specific cataract and management of astigmatism ~ Second generation GEN2~ 15*femtosecond laser device for

  7. Slide 7: Evolved LENSAR Laser. Evolved Outcomes.

    Evolved LENSVAR® Laser. Evolved Outcomes. Streamline? I Streamline? It st m Streamline® IV Wireless Integration & IntellAxis-C° Bs IntellAxis Refractive - b BE copsulorhexis® Fiat and ONLY laser to make agnment ‘marks on the caps to sue IL plcement to pefecly align tothe patients! ‘stgmatism for imp

  8. Slide 8: Laser Assisted Cataract Surgery Global Market

    Laser Assisted Cataract Surgery Global Market

  9. Slide 9: Innovation Earned LENSAR Significant Market Share

    = Innovation Earned LENSAR Significant Market Share Estimated 2019 Revenue Market Share LENSAR Procedures per Year of FLACS Participants All Other 5% 2012" 2013 2014 2015 2016 2017-2018 2019, Est

  10. Slide 10: Cataract is Highest Volume Surgical Procedure Worldwide

    Cataract is Highest Volume Surgical Procedure Worldwide 29 Million global cataract/refractive lens exchange surgical procedures estimated in 2019 Ultrasonic Phacoemulsification (USP) FLACS+USP ~ 815,000 Procedures 2024 FLACS forecast in cataract/refractive lens exchange procedures is 1 million 2024

  11. Slide 11: Laser Assisted Cataract Surgery (LACS) Global Market Overview

    == Laser Assisted Cataract Surgery (LACS) Global Market Overview Worldwide 2018 Projected Year-End Laser * Global market penetration World Region Installations Cataract/RLE Penetration (LACS procedures) grew to 13% in 2018 United States 1,086 423,729 10.6% * LACS procedures expected to grow Western

  12. Slide 12: LENSAR Global Presence has Increased Steadily

    LENSAR Global Presence has Increased Steadily w= Procedure volume grew 30% YOY since 2016 Global Forecast LENSAR Forecast | Percent to Global 13% “3% 2029 LENSAR United states aaa procedure market share LENSAR installed systems Western Europe 2a = 387 = 38% perform 73% more procedures | Other Wealth

  13. Slide 13: Key Factors Driving Growth in the Intraocular Lens Market

    = Key Factors Driving Growth in the Intraocular Lens Market == Growing confidence in cataract surgery is a byproduct of better technology Premium IOL penetration expected to grow from 17% to 24% by 2023; drives FLACS growth — New IOLs drive need for automation/accuracy that only lasers provide Deman

  14. Slide 14: The LENSAR Difference

    ae The LENSAR Difference

  15. Slide 15: The Surgeon's Perspective on LENSAR Technology

    The Surgeon’s Perspective on LENSAR Technology “What | enjoy is the refractive outcomes and the predictability that the LENSAR® Laser System now affords me asit relates to astigmatism correction with toric IOL placement. The IntelliAxis Refractive Capsulorhexis places refractive marks on the capsule

  16. Slide 16: Essence of LENSAR's Differentiation

    Essence of LENSAR’s Differentiation == IntelliAxis Refractive Capsulorhexis - Unique and Proprietary Technology IntelliAxis Refractive Capsulorhex' Creates pair of small tabs on the capsular rim guided by Iris Registration to identify the intended axis as part of the laser Refractive Capsulorhexis T

  17. Slide 17: LENSAR: Tools to Enable Superior Outcomes

    == LENSAR: Tools to Enable Superior Outcomes . Postoperative Results. | [SSS Postoperative Results <0) = 100% of eyes with toric IOL ” + 94% of eyes that received treatment were <0.5 D I — : an EDOF toric IOL were 50.5 D post-op and MRSE was -0.14 + 0.44 D (N=115) 15 + Astigmatism was reduced from 1

  18. Slide 18: Improving Outcomes in Astigmatism Management

    Improving Outcomes in Astigmatism Management 8

  19. Slide 19: Unmet Need and Room for Improvement

    Unmet Need and Room for Improvement Spectacle-independence must include management of astigmatism 70-90% of patients have treatable astigmatism; the majority of these remain uncorrected” 19.1% vax Hi, MD Keratometry Database Prevalence 11.2% 7.8% The mean percentage of patients who were within 0.5 d

  20. Slide 20: Best-in-Class Astigmatism Management Capability

    Best-in-Class Astigmatism Management Capability LASIK, PRK Significant contraindications (dry-eye), flaps Secondary procedures take additional patient and surgeon time, visual recovery time, added cost Al incisions (manual with blades) lack precision and reproducibility Other cataract laser systems

  21. Slide 21: 2

    2

  22. Slide 22: GEN2 - All-in-One Femto Phaco Device

    GEN2 -— All-in-One Femto Phaco Device 1st femtosecond laser device that can perform all cataracts Easily replaces older technology - Configured anywhere in the operating room; increasing trend toward in-office surgical suites — Integrated with ultrasound (phaco); seamlessly switches from femto to ph

  23. Slide 23: Market- and Innovation-Driven Opportunity

    == Market- and Innovation-Driven Opportunity Sales of new phaco systems has slowed due to lack of new technology advancement — Estimated placement of ~8,300 phacos in 2019 (1.7 B); estimated placement in 2024 is~9,600 phacos ~ Market prefers new technology geared toward improving safety, efficiency,

  24. Slide 24: Poised for Success

    = Poised for Success Development Update Commercial Potential * Laser engine: 1% Breadboard completed in * Best-in-Class: GEN2 recognized as single July; exploring COGS reductions platform femto phaco device * Optics path: 2"4 Breadboard completed in * GEN2 has potential to generate additional Octobe

  25. Slide 25: Intellectual Property, Leadership, Financials

    —==—————— iy) © _, Intellectual Property, Leadership, Financials 25

  26. Slide 26: Broad and Deep Intellectual Property Portfolio

    == Broad and Deep Intellectual Property Portfolio LENSAR Augmented Reality platform, fragmentation, patient interface fully covered + Royalty-free licenses for blocking patents ely ee Key Patent Elements * Issued patents: 31 U.S. and 55 foreign * Augmented reality * Fragmentation * Cataract treatmen

  27. Slide 27: LENSAR's Leadership has Deep Expertise in Cataract Surgery

    LENSAR’s Leadership has Deep Expertise in Cataract Surgery and Device Development and Commercialization Nick Curtis Alan Connaughton Chief Executive Officer Chief Operating Officer William Link, PhD Founder, Versant Ventures & Flying L Partners Richard Lindstrom, MD Founder & Attending Surgeon, Minn

  28. Slide 28: Revenue Growth Driving Near Breakeven Operating Results

    Revenue Growth Driving Near Breakeven Operating Results + Strong YOY double digit revenue growth 2017 2018 | 2019Q2 YTD * Q2 2019 revenue growth 30% Revenue $20,636 $24,652 $14,148 ~ Corresponding increases in number of worldwide procedures performed Net Loss $(12,907) $(5,348) $(3,236) * Q2 2019 op

  29. Slide 29: Investment Summary

    Investment Summary + _ Established innovation leader with highly respected leadership team and board of directors * Best-in-class technology platform with Streamline® IV; market-leading innovation with GEN2 — Streamline® IV - enables optimal treatment of tissue-specific cataract and management of as

  30. Slide 30: Increasing Value by Continuing to Evolve

    yes fff |LENSAR ~lAY, ZW | (RN j Increasing Value by Continuing to Evolve

PDL Biopharma — Investor Presentation (October 2019) on 6ix